UK allergy drugs
This article was originally published in The Tan Sheet
Executive Summary
Committee on Safety of Medicines proposes lifting Rx restrictions to allow pharmacy sale of azelastine hydrochloride eye drops (Asta's Rx Optivar in the U.S.) for "treatment of seasonal and perennial allergic conjunctivitis in adults and children" ages 12 and older, according to Jan. 22 consultation letter. CSM also invites comments on proposal to allow pharmacy sale of fluticasone proprionate (GlaxoSmithKline's Flonase in the U.S.) non-pressurized nasal spray for prevention and treatment of allergic rhinitis in persons 18 and older...